Beta thalassemia major in a developing country: Epidemiological, clinical and evolutionary aspects

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 5, Issue 1, 2013, Pages

  Bejaoui, Mohamed ^a   Guirat, Naouel ^a  

^a CENTRE NATIONAL DE GREFFE DE MOELLE OSSEUSE   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BENZATHINE PENICILLIN; CHELATING AGENT; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; PENICILLIN DERIVATIVE;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ARTICLE; BACTERIAL INFECTION; BLOOD TRANSFUSION REACTION; CAUSE OF DEATH; CHILD; CHOLECYSTECTOMY; CHOLELITHIASIS; DELAYED PUBERTY; DIABETES MELLITUS; DRUG FATALITY; ECHOGRAPHY; ENDOCRINE DISEASE; EPIDEMIOLOGICAL DATA; FATALITY; FERRITIN BLOOD LEVEL; GENETIC SCREENING; GROWTH RETARDATION; HEALTH EDUCATION; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEPATITIS B; HEPATITIS C; HETEROZYGOTE; HUMAN; HYPERFERRITINEMIA; INCIDENCE; INFANT; INFECTION PREVENTION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MOLECULAR EVOLUTION; PRESCHOOL CHILD; PROPHYLAXIS; PULMONARY HYPERTENSION; QUESTIONNAIRE; SCHOOL CHILD; SPLENECTOMY; THALASSEMIA MAJOR; VACCINATION; CHELATION THERAPY; CLINICAL FEATURE; DEMOGRAPHY; DESCRIPTIVE RESEARCH; DEVELOPING COUNTRY; DISEASE SEVERITY; FEMALE; HYPOTHYROIDISM; INFECTION; MALE; MORTALITY; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SCREENING; TUNISIA;

EID: 84877954331     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2013.002     Document Type: Article

References (34)

1. Fattoum S. Evolution of Hemoglobinopathy Prevention in Africa: Results, Problems and Prospect. Mediterr J Hematol Infect Dis. 2009;1:e2009005
2. Angelucci E, Pilo F, Targhetta C, Pettinau M, Depau C, Cogoni C, Usai S, Pani M, Dess L, Baronciani D. Hematopoietic stem cell transplantation in talassemia and related disorders. Mediterr J Hematol Infect Dis. 2009;1:e2009015
3. Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, Vichinsky EP. Alloimmunization and erythrocyte autoimmunization in transfusion dependant thalassemia patients of predominantly Asian descent. Blood 2000;96:3369-3373
4. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The retrovirus Epidemiology Donor study. NEngl J Med, http://dx.doi.org/10.1056/NEJM199606273342601, 1996;334: 1685-1690.
5. Ahrens N, Pruss A, Kohne A, Kiesewetter H, Salama A. Coexistence of autoantibodies and alloantibodies to red cells due to blood transfusion. Transfusion. http://dx.doi.org/10.1111/j.1537-2995.2007.01194.x 2007; 47:813-816
6. Ghosh S., Bandyopadhyay SK, Bandyopadhyay R, Ro, Maisnam I, Ghosh M.K. A study on endocrine dysfunction in thalassaemia.J Indian Med Assoc2008; 106: 655-659
7. Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou EK, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factorsover the period 1908-2004. Haematologica 2006;91: 1187-1192
8. Wonke B, Hoffbrand AV, Brown D, Dusheiko G. Antibody to hepatitis C virus in multiply transfused patients with thalassaemiamajor.J ClinPatho1990;43: 638-640.
9. Angelucci E. Antibodies to hepatitis C virus in thalassaemia.Haematologica1994;79: 353-355.
10. Young PP, Uzieblo A, Trulock E, Lublin DM, Goodnough LT. Autoantibody formation after alloimmunization: are blood transfusions a risk factor for autoimmune hemolyticanemia?.Transfusion, http://dx.doi.org/10.1046/j.0041-1132.2003.00589.x, 2004; 44: 67-72.
11. Ameen R, Al-Shemmari S, Al-Humood S, ChowdhurryRI,Al-Eyaadi O, Al-Bashir A.RBC alloimmunization and autoimmunization among transfusion-dependant Arab thalassemia patients. Transfusion. http://dx.doi.org/10.1046/j.1537-2995.2003.00549.x 2003;43: 1604-1610
12. Gader AMA, Al Ghomlas AK, Al Momen AK. Transfusion medicine in developing country-Alloantibodies to red blood cells in multitransfused patients in Saudi Arabia.Transf. apheresis science2008;39:199-204.
13. Bhatti FA, Salamat N, Nadeem A, Shabbir NJ. Red cell immunization in beta thalassaemiamajor.Coll Physicians Surg Pak2004;14: 657-660.
14. Dhouib N,Mezri M,Hmida H,Mellouli F, Kaabi H, Ouderni M, et al. High frequency ofautoimmunizationamong transfusion-dependent Tunisian thalassemia patients. Transf apheresis 2011;45: 199-20
15. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, et al. Survivalanddiseasecomplications in thalassemia major. Ann N Y AcadSci. http://dx.doi.org/10.1111/j.1749-6632.1998.tb10479.x, 1998;850: 227-231
16. CappelliniMD,Bejaoui M, Agaoglu L, Canatan D, CapraM,Cohen A, et al.Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 2011;22:115-120
17. ChimomasD,Smith AL, BrausteinJ,Finkelstein Y, Pereira L, Bergmann AK, et al.Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood. http://dx.doi.org/10.1182/blood-2009-05-222729 2009;114:4009-4013
18. Cao A., Galanello R., Rosatelli MC., Argiolu F., DeVirgiliis S. Clinical experience of management of thalassemia: theSardinian experience. Semin Hematol 1996; 33:66-75
19. Rashid J, Khalil M, Natiq M, Anwar S, Nazir MM. Etiology of congestive heart failure in children. Pak Ped J 2003; 27: 145-51.
20. Aydinok Y, Darcan S, Polat A, Kavakli K, Nigli G, Coker M et al. J Endocrine complications in patients with beta-thalassemia major.Trop Pediatr2002;48:50-54.
21. Fung EB, Harmatz PR, Lee PD, Milet M, Bellevue R, Jeng MR, et al.: Multi-Centre Study of Iron Overload Research Group.Increased prevalence of iron-overload associated endocrinopathy in thalassaemiaversus sickle-cell disease. Br J Haematol 2006; 135:574-582.
22. Jensen CE, Tuck SM, Old J, et al. Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with beta-thalassaemia. Eur J Haematol. http://dx.doi.org/10.1111/j.1600-0609.1997.tb00729.x 1997;59: 76-81
23. Italian Working Group on Endocrine Complications in Nonendocrine Diseases Multicentre study on prevalence of endocrine complications in thalassaemia major. Clin Endocrinol 1995;42:581-586.
24. Brittenham GM, Griffith PM, NienhuisAW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of desferoxamine in preventingcomplications of ironoverload in patients with thalassemia major. N Engl J Med 1994;331:567-573
25. De Sanctis V, Eleftheriou A, Malaventura C. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev 2004;2:249-255
26. Fosburg MT, Nathan D.G. Treatment of Cooley's anemia. Blood 1990;76: 435-444
27. Bisharat N, Omari H, Lavi I. Risk of Infection and Death Among Post-splenectomy Patients. Journal of Infection. http://dx.doi.org/10.1053/jinf.2001.0904 2001;43:182-186
28. Resende V, Petroianu A. Functions of the splenic remnant after subtotal splenectomy for treatment of severe splenic injuries. Am Surg2003. http://dx.doi.org/10.1016/S0002-9610(02)01407-1;185:311-315
29. Rice HE, Oldham KT, Hillery CA, Skinner MA, O'Hara SM,Ware RE. Clinical and hematologic benefits of partial splenectomy for congenital hemolytic anemias in children. Ann Surg. http://dx.doi.org/10.1097/01.SLA.0000048453.61168.8F, 2003;237:281-288
30. Hahalis G, Alexopoulos D, Kremastinos DT, Zoumbos NC. Heart failure in beta thalassemia syndromes: a decade of progress. Am J Med1 2005;18: 957-967.
31. Olivieri NF, McGee A, Liu P, Koren G, Freedman MH, Benson L. Cardiac disease-free survival in patients with thalassemia major treated with subcutaneous deferoxamine. An update of the Toronto cohort.Ann NY AcadSci, http://dx.doi.org/10.1111/j.1749-6632.1990.tb24374.x, 1990;612:585-586
32. Ladis V, Chouliaras G, Bedousi H, et al. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y AcadSc i, http://dx.doi.org/10.1196/annals.1345.067, 2005;1054:445-450
33. Cao A, Rosatelli C, Galanello R, Monni G, Olla G, Cossu P. et al. The prevention of thalassemia in Sardinia. Clin Genet. 1989; 36:277-85.
34. Buki MK, Qayum I, Siddiqui N. Prevalence and preventive measures for thalassemia in Hazara region of NWFP Pakistan. JAMC 1998; 10: 28-31.